# An atypical case of AA amyloidosis and its association with pulmonary silicosis

Filipa Guimarães<sup>1\*</sup> , Miguel Borges Silva<sup>1</sup>, João Correia-Pinto<sup>2</sup> (b), Ana Branco<sup>3</sup>, António Furtado<sup>1</sup>, Fátima Magalhães<sup>2</sup>, José Vasco Barreto<sup>1</sup> (), Raquel Calisto<sup>1</sup> (), Nídia Pereira<sup>1</sup> ()

#### **European Journal of Medical Case Reports**

Volume 4(9):296-300 © EJMCR. https://www.ejmcr.com/ Reprints and permissions: https://www.discoverpublish.com/ https://doi.org/10.24911/ejmcr/ 173-1581872222

# ABSTRACT

Background: Amyloid fibrils are protein polymers. Functional amyloids play a beneficial role in a variety of physiologic processes. Amyloidosis results from the accumulation of pathogenic amyloids in a variety of tissues.

Case Presentation: The authors present a case of a 60-year-old male with a pseudotumoral silicosis, a history of intermittent fever, and renal insufficiency with intermittent proteinuria (maximum of 3 g/dl). The diagnosis of amyloidosis was made from multiple biopsies. During the investigation, it was never possible to characterize the subtype of amyloidosis [the patient had findings either in favor of AL amyloidosis and AA amyloidosis (AA)]. A definite diagnosis was only obtained from an autopsy, and AA was found to be the subtype.

Conclusion: At the time of this publication and to the best of authors' knowledge, AA has never been described to be associated with pseudotumoral form of pulmonary silicosis. We believe that an inflammatory response associated with pulmonary silicosis was the trigger to the development of AA.

Keywords: Amyloidosis AA, amyloidosis AL, systemic amyloidosis, pseudotumoral silicosis.

Received: 16 February 2020	Accepted: 10 July 2020	Correspondence to: Filipa Guimarães
Type of Article: CASE REPORT	Specialty: Internal Medicine	*Internal Medicine Department, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Porto, Portugal.
Funding: None.		<b>Email:</b> lipaguima@gmail.com Full list of author information is available at the end of the article.
Declaration of conflicting interests no conflict of interests regarding th		

# **Background**

Amyloidosis is a heterogeneous group of diseases caused by the extracellular deposition of autologous fibrillar proteins, which aggregate into a three-dimensional *B*-lamina disposition that impairs normal organ function [1]. The main subtypes of systemic amyloidosis are primary AL amyloidosis (AL), secondary AA amyloidosis (AA) amyloidosis, familial amyloidosis, senile amyloidosis, and ß2-microglobulin-related amyloidosis [2]. AL is the most prevalent subtype in developed countries. Due to its association with inflammatory and infectious diseases, AA is also one of the most reported subtypes [3].

Amyloid deposits in AA are composed mainly of the serum amyloid A (SAA) protein, an apolipoprotein of high-density lipoproteins that serves as a dynamic acute phase reactant [4]. In AL, there is an abnormal folding that results in either a proteolytic event or an amino acid sequence that renders a light chain thermodynamically unstable and prone to self-aggregation [5].

Clinically, any organ tissue can be involved in any type of amyloidosis, which often makes a distinction between them a difficult task. While AA more often presents with renal disease (ranging from subnephrotic proteinuria to overt nephrotic syndrome and end-stage

renal disease) in patients with underlying chronic inflammatory conditions, AL more frequently presents with cardiomyopathy, a rare occurrence in the former [6,7]. By the conjugation of both clinical and histological features, it is usually possible to distinguish the two subtypes.

Pulmonary silicosis is an occupational disease caused by silica inhalation. Its pseudotumoral form is very rare. It is known to be associated with pulmonary tuberculosis and lung cancer. Furthermore, recent studies suggest that its physiopathology is based on chronic inflammation, by activation of the inflammasome, triggered by silica crystals [8,9].

# **Case Presentation**

The patient is a 66-year-old Caucasian man with a background of pseudotumoral silicosis and chronic renal disease (Stage b A3, with a creatinine range between 1.8 and 2.0 mg/dl and a TFG 20 ml/minutes/m<sup>2</sup>). He had a 7-year history of intermittent fever and proteinuria (maximum of 3 g/dl). He was admitted following a 7-day period of diarrhea and fever. On the previous weeks, he had severe asthenia and significant weight loss. He was cachectic, febrile (38°C), with low blood pressure (85/56 mmHg), and no other major findings on physical examination. Macroscopic hematuria was detected. Blood tests showed mild normocytic anemia (Hb 10.6 g/dl), C-reactive protein of 45 mg/l, mild leukocytosis (12,000 cells per mm<sup>3</sup>) with neutrophilia (7,000 per mm<sup>3</sup>), and creatinine 4.5 mg/dl. Platelet levels were normal, and no liver changes were found. The abdominal and thorax image showed no acute changes.

In the presumption of sepsis, empirical antibiotics and fluids were initiated, but symptoms persisted despite 7 days of treatment. Blood and urinary cultures were negative. Due to persistent hematuria and diarrhea, vesical and rectal biopsies were obtained, revealing the presence of amyloid. The patient became anuric and started hemodialysis. For this reason, a urinary immunoelectrophoresis could not be obtained. Because of the multisystemic impairment, such as hypotension, diarrhea, hematuria, and functional deterioration, other biopsies were performed (skin, thyroid, and salivary gland), and they were all positive for amyloid (Figures 1–4). Electromyography confirmed motor-sensitive polyneuropathy. The whole picture was attributable to systemic amyloidosis.

An investigation was conducted to identify the subtype of amyloid: rheumatoid factor was slightly positive, and the rest of autoimmunity study is negative (ANCA, anti-endomysium, anti-Scl70, anti-RNA polymerase, and cryoglobulins); monoclonal gamopathy was excluded, as well as familial mediterranean fever (MEFV gene sequentiation),




Figure I. Amyloid deposits on more than 50% of the glommerules (kidney)-right; congo red positivity (kidney)-Left.




Figure 2. Subendocardic amyloid deposits (heart).




Figure 3. Diffuse amyloid deposition (thyroid).




Figure 4. Congo red positivity (liver).

TRAPS syndrome (TNFRSF1A gene sequentiation), Fabry disease (alfa-galactosidade A activity), active and latent tuberculosis, and also lymphoma. The serum amyloid protein A was positive in immunohistochemical analysis, and there was a restriction for lambda chains, suggesting that it might be an AA or AL type. On the other hand, the potassium permanganate test, which is considered positive when the sample loses de "Congo red" staining, favored AA type (also suggested by the positive rheumatoid factor and fever). These tests were performed at different hospitals, and the results were always concordant.

Corticotherapy was initiated with prednisolone in a dose of 1 mg/kg/day, with no clinical response. The patient died. An autopsy was consented by the family. A better characterization of the amyloid was made with immunoelectronic microscopy: amyloid fibrils were intensely and specifically immunoassayed with a monoclonal anti-SAA antibody, whereas anti-kappa and lambda light chains, anti-transthyretin, and anti-apolipoprotein AI antibodies were all negative, excluding AL and confirming AA subtype. All the inflammatory causes that are known to be associated with AA were also excluded.

# Discussion

Amyloidosis is a heterogeneous group of diseases. All organs can be affected in AL, except the central nervous system. In the AA subtype, renal and gastrointestinal involvement is common (proteinuria, malabsorption, intestinal pseudo-obstruction, diarrhea, or bleeding); peripheral polyneuropathy and skin involvement are rare [10]. In the patient, the clinical presentation had elements of the two entities. The abrupt evolution observed at the end is not common in any kind of amyloidosis.

All tests performed at the center for identifying the amyloid subtype were inconclusive. Immunohistochemistry tests showed contradictory results. This technique is usually sufficient to determine the fibril protein type in AA amyloid, as there are excellent commercially available antibodies, but tandem mass spectrometry can be useful in nondiagnostic or un-interpretable cases. The samples were sent to an international center, and immunoelectron microscopy was performed, revealing the AA subtype.

We have excluded all the conditions usually associated with AA; no infectious, autoimmune, or inflammatory disorder was found. We excluded the most common genetic conditions and no clinical or physical signs suggested other genetic disorders. The only disease that could be presumed to be associated with AA was the pseudotumoral silicosis. The patient presented with mild leukocytosis with neutrophilia (documented 4 years before admission) possibly traducing a chronic inflammatory state. Despite common, no thrombocytosis was found [11]. Reviewing the international literature for similar cases, we found an anecdotal report described in 1932 and a case presented in a Spanish meeting of Nephology, but no association with the pseudotumoral form of silicosis [12].

Recent studies suggest the association between silica exposure and autoinflammatory diseases [13,14]. Silicosis is characterized by chronic inflammation in the upper lobes of the lungs. The ingestion of silica particles by alveolar macrophages initiates an inflammatory response. Silica exposure, per se, is associated with rheumatoid factor positivity. Pseudotumoral silicosis is known to be associated with chronic inflammation [15]. We hypothesize that this inflammatory state could be the feature associating with silica exposure and amyloidosis. It has been suggested that silica induces inflammasome activation leading to the maturation and release of proinflammatory cytokines. NLRP3 is the most studied inflammasome, leading to the release of interleukins 1 and 18. This mechanism justifies the association between silicosis and inflammation [9]. There is a speculation that this mechanism is also associated with triggering autoimmune diseases, and we suppose that this could also represent the trigger to an AA.

# Conclusion

At the time of this publication and to the best of authors' knowledge, AA has never been described to be associated with pseudotumoral form of pulmonary silicosis. We believe that an inflammatory response associated with pulmonary silicosis was the trigger to the development of AA.

Amyloidosis is a common condition among elder patients.

There are many subtypes of systemic amyloidosis: AL, AA, familial, senile, and ß2-microglobulin-related amyloidosis.

AL is a consequence of a plasma cell disorder characterized by amyloid deposits of immunoglobulin light chains

AA is associated with inflammatory diseases.

There are no specific symptoms of amyloidosis but impaired renal function and anemia are common.

The authors present a disease association of AA that has never been described (pulmonary silicosis).

## What is new?

There are only two cases in which AA and its association with pulmonary silicosis are proposed: One dated from 1930, and a recent one in a Spanish meeting (no publication). This is the first one to establish a possible relationship between AA and pseudotumoral form of sylicosis.

# **List of Abbreviations**

AA	AA amyloidosis	
AL	AL amyloidosis	
SAA	Serum amyloid A	

## **Consent for publication**

Written informed consent was taken from the family of the patient.

#### **Ethical approval**

Ethical approval is not required at the institution for publishing an anonymous case report.

#### **Author details**

Filipa Guimarães<sup>1</sup>, Miguel Borges Silva<sup>1</sup>, João Correia-Pinto<sup>2</sup>, Ana Branco<sup>3</sup>, António Furtado<sup>1</sup>, Fátima Magalhães<sup>2</sup>, José Vasco Barreto<sup>1</sup>, Raquel Calisto<sup>1</sup>, Nídia Pereira<sup>1</sup>

- 1. Internal Medicine Department, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Porto, Portugal
- 2. Pathologic Anatomy Department, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Porto, Portugal
- <sup>3</sup>Nephrology Department, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Porto, Portugal

# References

- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. https://doi. org/10.1056/NEJMra023144
- Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–41. https://doi.org/10.1146/annurev.med.57.121304.131243
- Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SDJ, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525–32.
- Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64– 9. https://doi.org/10.1097/00062752-200001000-00012
- Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005;105:794– 803. https://doi.org/10.1182/blood-2004-04-1424
- Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91. https://doi.org/10.1056/ NEJMoa013354
- Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 2000;82(8):1501–5.
- Leung CC, Sun Yu IT, Chen W. Silicosis. Lancet. 2012;379:2008–18. https://doi.org/10.1016/ S0140-6736(12)60235-9
- Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization. Nat Immunol. 2008;9(8):847–856.
- Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71. https://doi.org/10.1038/ni.1631
- Rolfes V, Ribeiro LS, Hawwari I, Böttcher L, Rosero N, Maasewerd S, et al. Platelets fuel the inflammasome activation of innate immune cells. Cell Rep. 2020;31(6):107615. https://doi.org/10.1016/j.celrep.2020.107615
- 12. Carey J. Pneumosilicosis and amyloidosis. Report a case of asymptomatic pulmonart silicosis and amyloid kidney; death from uremia. Ann Intern Med. 1933;6(8):1106–14. https://doi.org/10.7326/0003-4819-6-8-1106
- Pollard K. Environment, autoantibodies, and autoimmunity. Front Immunol. 2015;6:60. https://doi.org/10.3389/ fimmu.2015.00060
- Zaghi G, Koga F, Nisihara R, Skare T, Handar A, Utiyama R, et al. Autoantibodies in silicosis patients and in silica-exposed individuals. Rheumatol Int. 2010;30(8):1071–5. https://doi.org/10.1007/s00296-009-1116-z
- Oţelea MR, Andrei N, Moise LG. The significance of the neutrophil to lymphocyte ratio in silicosis. J Contemp Clin Pract. 2018;4(2):53-59. https://doi.org/10.18683/ jccp.2018.1036

Summary of the case			
1	Patient (gender, age)	Male, 66	
2	Final diagnosis	AA amyloidosis due to pseudotumoral silicosis	
3	Symptoms	Hypotension, diarrhea, hematuria, renal dysfunction, and functional deterioration	
4	Medications	Corticotherapy	
5	Clinical procedure	NA	
6	Specialty	Internal medicine	